MedChemComm p. 963 - 968 (2018)
Update date:2022-08-02
Topics:
Pippione, Agnese C.
Sainas, Stefano
Federico, Antonella
Lupino, Elisa
Piccinini, Marco
Kubbutat, Michael
Contreras, Jean-Marie
Morice, Christophe
Barge, Alessandro
Ducime, Alex
Boschi, Donatella
Al-Karadaghi, Salam
Lolli, Marco L.
NF-κB-inducing kinase (NIK), an oncogenic drug target that is associated with various cancers, is a central signalling component of the non-canonical pathway. A blind screening process, which established that amino pyrazole related scaffolds have an effect on IKKbeta, led to a hit-to-lead optimization process that identified the aminopyrazole 3a as a low μM selective NIK inhibitor. Compound 3a effectively inhibited the NIK-dependent activation of the NF-κB pathway in tumour cells, confirming its selective inhibitory profile.
View MoreShanghai Bocimed Pharmaceutical Co., Ltd.
website:http://www.bocimed.com
Contact:+86-21-68861632
Address:Building 1, Lane 647, Songtao Road, Zhangjiang High-Tech Park, Shanghai
Zibo Fuxi'er Chemical Co.,Ltd (Shanxian Fuxi'er Chemical Co.,Ltd)
Contact:+86-533-2091422
Address:Eastern 4 on the 3th Road ,Liangxiang Industrial Park, Zibo city ,Shandong,China
zhuzhou zhongle chemical co. ltd.
Contact:+86-0731 28228409
Address:Zhuzhou, Hunan, China
Suzhou Chiral Pharmaceuticals Co., Ltd.
Contact:86-0512-63197058
Address:Building A, No. 2358, Chang'an Road, Wujiang Science Park
Contact:+86-0512-62857507
Address:Boji Science Park, No1688C,Taishan road, Suzhou ,China
Doi:10.1021/ja01513a058
(1959)Doi:10.1016/j.poly.2004.06.014
(2004)Doi:10.1007/s11094-020-02172-4
(2020)Doi:10.1021/ja00395a071
(1981)Doi:10.1055/s-1980-29275
(1980)Doi:10.1002/ejoc.200400291
(2004)